{"product_id":"ibrx-bcg-matrix","title":"(IBRX) ImmunityBio, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis ImmunityBio, Inc. BCG Matrix is a company-specific strategic analysis that helps you see how its products or business units may fall into Stars, Cash Cows, Question Marks, or Dogs. The content on this page is a real preview of the actual deliverable, so you can review the format and substance before buying. Purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eANKTIVA, 1 approved product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eANKTIVA is ImmunityBio, Inc.'s only approved product, and the FDA cleared it in 2024 for BCG-unresponsive NMIBC CIS with or without papillary tumors. It is the company’s first commercial launch and the clearest Stars asset in the BCG matrix, with the strongest near-term growth runway through 2025. In a niche where BCG fails in many patients, ANKTIVA has a direct shot at becoming the core revenue driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG-unresponsive NMIBC CIS\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBCG-unresponsive NMIBC CIS is a high-need bladder cancer niche with only a few approved options, including pembrolizumab and nadofaragene firadenovec. ImmunityBio, Inc.’s IL-15-based ANKTIVA + BCG was FDA-approved in April 2024 for this setting, backed by a 71% complete response rate and 56% of responders lasting at least 12 months.\u003c\/p\u003e\n\u003cp\u003eThat mix of clear unmet need and differentiated data makes it a strong Star candidate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePapillary NMIBC expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePapillary NMIBC can meaningfully expand ImmunityBio, Inc.'s bladder franchise beyond CIS, a segment that makes up most of the roughly 75% of bladder cancers diagnosed as non-muscle-invasive disease. That widens the treatable pool and can lift adoption if clinical and regulatory support keeps building. In a market where bladder cancer drives over 80,000 U.S. cases a year, a broader label would strengthen the Star profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBladder cancer commercial launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio’s bladder cancer launch, led by Anktiva for BCG-unresponsive NMIBC with CIS, moves the story from R\u0026amp;D to revenue. The U.S. sees about 83,000 new bladder cancer cases a year, so even early uptake can compound if reimbursement, physician adoption, and supply scale. This is still a growth-heavy launch, not a mature cash engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCommercial stage now\u003c\/li\u003e\n\u003cli\u003eReimbursement drives uptake\u003c\/li\u003e\n\u003cli\u003eAdoption can compound sales\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNK and T cell activation platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eANKTIVA anchors ImmunityBio’s NK and T cell activation platform, which is a classic Star trait because one immune backbone can support several oncology combinations. In 2024, ANKTIVA was the first FDA-approved IL-15 agonist, and ImmunityBio reported product revenue of about $50 million, showing early commercial traction for a platform built to scale across tumors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSingle biology, multiple combo paths\u003c\/li\u003e\n\u003cli\u003eNK and T cell activation is the core\u003c\/li\u003e\n\u003cli\u003eFirst FDA-approved IL-15 agonist\u003c\/li\u003e\n\u003cli\u003ePlatform leverage supports Star status\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eANKTIVA: ImmunityBio’s First Big Growth Engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eANKTIVA is ImmunityBio, Inc.'s clear Star: it is the only approved product, launched in 2024 for BCG-unresponsive NMIBC CIS, and reported about 71% complete response with 56% of responders lasting at least 12 months. That gives it the best near-term growth path in a niche with few options and about 83,000 U.S. bladder cancer cases a year.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar driver\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eANKTIVA approval\u003c\/td\u003e\n\u003ctd\u003eApril 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCR rate\u003c\/td\u003e\n\u003ctd\u003e71%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12-month durability\u003c\/td\u003e\n\u003ctd\u003e56%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 product revenue\u003c\/td\u003e\n\u003ctd\u003eAbout $50 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix view of ImmunityBio’s portfolio, showing where to invest, hold, or exit across Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG Matrix view of ImmunityBio, Inc. to spotlight pain points and prioritize portfolio moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for ImmunityBio, Inc., helping users verify key assumptions quickly and make better-informed decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo true mature cash cow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBy end-2025, ImmunityBio, Inc. still had just 1 commercial product, ANKTIVA, and no broad mature portfolio to harvest steady cash from. Most of its other assets remained trial-stage or growth-stage, so they were still consuming capital rather than funding the business. That leaves the BCG matrix with limited true Cash Cow inventory and very little mature, repeatable cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eANKTIVA recurring U.S. sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eANKTIVA’s U.S. sales are recurring, not one-off, because the therapy is used in repeat treatment cycles for a chronic oncology niche. In ImmunityBio, Inc.’s mix, that makes it the closest thing to a Cash Cow: if demand stays steady, each added sale should need less new R\u0026amp;D spend and can lift operating cash flow. That matters because the U.S. launch is still early, so even modest, stable prescription growth can improve margins faster than a new product buildout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment collaboration receipts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. lists government collaborations with the National Cancer Institute and the National Institute on Deafness and Communication Disorders, and this kind of support can help offset R\u0026amp;D burn. It is steady, lower-risk cash flow, but it is not a scalable growth franchise. For a Cash Cow label, the value is funding stability, not margin expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicense portfolio income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio’s license portfolio spans 8 named partners: CytRx, EnGeneIC, GlobeImmune, IDRI, Sanford Health, Shenzhen Beike, Sorrento, and Viracta. That kind of income is usually modest, but it can repeat without the heavy cash burn of new R\u0026amp;D bets, so it fits BCG Cash Cows better than a pipeline story.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e8 licensing ties\u003c\/li\u003e\n\u003cli\u003eRepeatable, low-burn income\u003c\/li\u003e\n\u003cli\u003eMore stable than new pipeline risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing scale efficiencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. can get better unit economics as ANKTIVA volume rises, because the same plant, QC, and regulatory costs get spread over more doses and more treatment sites. That is classic Cash Cow behavior once a biologic launch matures and demand steadies.\u003c\/p\u003e\n\u003cp\u003eAs of 2025, ImmunityBio was still in the launch build phase, so the scale benefit is tied to dose growth, site expansion, and higher manufacturing utilization, not just price. The more recurring the orders, the more fixed cost leverage matters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher volume lowers cost per dose\u003c\/li\u003e\n\u003cli\u003eMore sites spread fixed costs wider\u003c\/li\u003e\n\u003cli\u003eMature launches can support cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio’s Cash Cows Remain Thin: ANKTIVA Carries the Load\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc. has very few Cash Cows. By end-2025, ANKTIVA was still its only commercial product, so recurring U.S. sales were the main stable cash source. Government collaborations and 8 licensing ties add modest, lower-burn income, but they do not yet form a true mature cash engine.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow source\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eANKTIVA\u003c\/td\u003e\n\u003ctd\u003e1 commercial product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicenses and grants\u003c\/td\u003e\n\u003ctd\u003e8 ties; modest repeat income\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eImmunityBio, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe ImmunityBio, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No sample pages, no placeholder text—just the complete, professionally formatted report. Once purchased, the full file is instantly available for download and use. What you see here is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ehAd5 SARS-CoV-2 vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ehAd5 SARS-CoV-2 vaccine is Dog-like for ImmunityBio, Inc. in 2025: the COVID vaccine market stayed dominated by Pfizer-BioNTech and Moderna, while this program had no disclosed commercial sales. Low share and weak growth mean it did not emerge as a market leader by year-end 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ehAd5 HIV vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ehAd5 HIV vaccine sits in the Dogs quadrant: HIV vaccine work is still a long, high-fail field, and ImmunityBio has not shown commercial scale here. In 2025, the Company reported no material HIV vaccine revenue, so returns remain uncertain against ongoing R\u0026amp;D spend. With no market leadership and a slow path to approval, this program looks like high effort for low near-term payoff.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy infectious-disease programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc.’s legacy infectious-disease programs sit outside the core bladder-cancer launch, so they are a Dogs-style drag unless they can prove late-stage value. These assets still face long development cycles and unclear differentiation, while the company’s 2025 focus remained ANKTIVA and bladder cancer. Without near-term clinical or commercial traction, they can keep using cash with limited payoff.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core partner-derived assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. has partner-derived legacy assets that fit a Dog profile when they do not move into late-stage development or near-term sales. In 2025, the market still treated these assets as non-core, while value creation stayed tied to ANKTIVA and other active programs.\u003c\/p\u003e\n\u003cp\u003eThat means cash can sit in dormant licenses instead of funding higher-return work. In biotech, idle partnered assets often stay on the books with little strategic lift unless a trial win or deal re-pricing changes the path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy licenses add cost, not growth.\u003c\/li\u003e\n\u003cli\u003eAdvancement is the key value trigger.\u003c\/li\u003e\n\u003cli\u003eIdle assets usually rank as Dogs.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEarly vaccine tooling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEarly vaccine tooling looks like a BCG \"Dog\" for ImmunityBio, Inc.: scientifically useful, but weak commercially without approved uses. In 2025, ImmunityBio still depended on Anktiva-linked sales, while platform tools alone had no clear market share or durable revenue stream. That makes this a cash-risk area unless new clinical data turns it into an approved product.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUseful science, weak sales\u003c\/li\u003e\n\u003cli\u003eNo approved indication, no scale\u003c\/li\u003e\n\u003cli\u003eHigh burn risk if trials slip\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio’s Dog Assets: Cash-Draining, Revenue-Light\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc.’s Dogs are the hAd5 SARS-CoV-2 vaccine, hAd5 HIV vaccine, and other legacy infectious-disease assets: in 2025 they had no disclosed commercial scale, no clear market share, and no near-term revenue driver. These programs stayed non-core while ANKTIVA and bladder cancer held company focus, so they still tied up cash with limited payoff. In BCG terms, they look like capital traps unless a late-stage win changes the profile.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog asset\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003cth\u003eBCG read\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ehAd5 SARS-CoV-2\u003c\/td\u003e\n\u003ctd\u003eNo disclosed sales\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ehAd5 HIV\u003c\/td\u003e\n\u003ctd\u003eNo material revenue\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy licenses\u003c\/td\u003e\n\u003ctd\u003eNon-core, idle\u003c\/td\u003e\n\u003ctd\u003eDog\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePancreatic cancer trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePancreatic cancer is a big, high-unmet-need market, with about 66,440 new U.S. cases and 51,750 deaths expected in 2025, and a 5-year survival rate near 13%. ImmunityBio, Inc.'s pancreatic program is still early and small, so it fits the Question Mark quadrant today. Strong trial data could lift its value fast, but revenue is not yet meaningful.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-small cell lung cancer trials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNSCLC is a huge immuno-oncology target: it makes up about 85% of lung cancers, and global lung cancer cases were about 2.5 million in 2022. ImmunityBio’s NSCLC work sits in trial-stage data, so the company is still proving share, not harvesting it. That fits a Question Mark: the upside is large, but adoption is still unproven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMuscle-invasive bladder cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMoving into muscle-invasive bladder cancer could open a larger market, since about 25% of bladder cancers are muscle-invasive and the global bladder cancer market is still expanding in 2025-2026. But ImmunityBio, Inc. is not a leader in this segment yet, and ANKTIVA remains tied mainly to NMIBC use. So this is still a Question Mark: high-growth upside, but future MIBC data must prove it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCombination immunotherapy studies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. uses combination immunotherapy to widen response and label breadth, and that can pay off if the data hold. The bet is still uncertain, though, because each added study keeps R\u0026amp;D spending high while the company has only one U.S. approved regimen for Anktiva in BCG-unresponsive NMIBC. In BCG terms, this fits a Question Mark: high upside, but heavy cash use until proof lands.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne approved U.S. regimen today.\u003c\/li\u003e\n\u003cli\u003eCombo trials aim to expand labels.\u003c\/li\u003e\n\u003cli\u003eValue depends on clinical readouts.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOther solid tumor expansions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunityBio, Inc. is pushing its platform into other solid tumors beyond bladder, but share is still tiny. That makes these programs classic Question Marks: the markets are huge, with global lung cancer near 2.5 million new cases, colorectal near 1.9 million, and breast near 2.3 million, yet commercial traction is still early.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig TAM, low share.\u003c\/li\u003e\n\u003cli\u003eHigh upside, high execution risk.\u003c\/li\u003e\n\u003cli\u003eProof of adoption is still limited.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunityBio’s Big Bets: High Upside, Still Too Early to Call a Star\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunityBio, Inc.’s Question Marks are early-stage but tied to large markets: pancreatic cancer, NSCLC, and bladder cancer. ANKTIVA has one U.S. approved use in BCG-unresponsive NMIBC, while broader combo trials are still unproven. The upside is real, but 2025-2026 revenue share is still too small to call any of these Stars.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003e2025-2026 status\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePancreatic\u003c\/td\u003e\n\u003ctd\u003e66,440 U.S. cases\u003c\/td\u003e\n\u003ctd\u003eHigh upside, low traction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNSCLC\u003c\/td\u003e\n\u003ctd\u003e2.5M global cases\u003c\/td\u003e\n\u003ctd\u003eBig TAM, trial-stage only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234590171401,"sku":"ibrx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/ibrx-bcg-matrix.webp?v=1785721544","url":"https:\/\/dcfanalyst.com\/products\/ibrx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}